Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on...

The immunosuppressive and immunomodulatory treatment of dermatological patients necessitates the regular review and updating of standard vaccinations and vaccines indicated for specific conditions. The German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute regularly publishes evidence-based vaccination recommendations, which are adapted to the current epidemiological situation and availability of vaccines. Since 2020, several changes have been made that are relevant for patients with dermato(onco)logical diseases: (1) COVID-19 was defined as a new viral disease and several vaccines have been introduced; (2) in response to the global Mpox outbreak in 2022, a non-replicating live vaccine based on the modified Ankara vaccinia virus, which was approved in 2013 for the prevention of smallpox, was given an indication extension; (3) a new inactivated high-dose vaccine was approved for influenza vaccination of persons aged 60 years and older; (4) a new 20-valent conjugate vaccine is available for pneumococcal vaccination; (5) two recombinant vaccines against the respiratory syncytial virus (RSV) were recently approved. This article discusses the correspondingly adapted STIKO recommendations for adults, with particular emphasis on their implementation in immunocompromised patients in dermatology.